SCHEMBL30130041

SCHEMBL30130041

C/C=C(\C)C(=O)Oc1ccc2[nH]c(CNC(=O)OC(C)(C)C)cc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ MTNR1A P48039 4/20 0.46
▸ MTNR1B P49286 3/20 0.46
▸ HPN P05981 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ GLA P06280 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ HIF1A Q16665 1/20 0.37
▸ KDM4A O75164 1/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ BCHE P06276 1/20 0.37
▸ CACNA1H O95180 1/20 0.37
▸ CACNA1B Q00975 1/20 0.37
▸ CACNA1C Q13936 1/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ PDGFRB P09619 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30130020 0.82 SMN1; SMN2 (0.48) SMN1; SMN2MTNR1AMTNR1BHPNKDM4E
SCHEMBL27195635 0.81 SMN1; SMN2 (0.47) SMN1; SMN2MTNR1AMTNR1BHPNKDM4E
SCHEMBL30130021 0.81 SMN1; SMN2 (0.47) SMN1; SMN2MTNR1AMTNR1BHPNKDM4E
SCHEMBL30130009 0.80 SMN1; SMN2 (0.47) SMN1; SMN2MTNR1AMTNR1BHPNKDM4E
SCHEMBL19964551 0.80 SMN1; SMN2 (0.55) SMN1; SMN2MTNR1AMTNR1BHPNMAPT
SCHEMBL30130048 0.79 SMN1; SMN2 (0.56) SMN1; SMN2MTNR1AMTNR1BHPNKDM4A
SCHEMBL30806238 0.79 LOXL2 (0.58) MTNR1AMTNR1BCA2PDGFRBFGFR1
SCHEMBL19964287 0.78 SMN1; SMN2 (0.55) SMN1; SMN2MTNR1AMTNR1BHPNKDM4E
Hydrochloric Acid SCHEMBL30129968 0.78 LOXL2 (0.57) MTNR1AMTNR1BCA2PDGFRBFGFR1
SCHEMBL30130002 0.77 MAOA (0.60) SMN1; SMN2KDM4EMAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124399-A1 NOVEL INDOLE DERIVATIVE, AND USE THEREOF FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS METACEN THERAPEUTICS (KR) 2024-04-18 — — US disclosed
EP-4353710-A1 NOVEL INDOLE DERIVATIVE, AND USE THEREOF FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS Metacen Therapeutics (KR) 2024-04-17 — — EP disclosed
WO-2022260491-A1 NOVEL INDOLE DERIVATIVE, AND USE THEREOF FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS 주식회사 메타센테라퓨틱스 2022-12-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124399-A1 NOVEL INDOLE DERIVATIVE, AND USE THEREOF FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS AGER, IDO1, IDO2 SMN1; SMN2 4446/4885MTNR1A 40/4885MTNR1B 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback